Singapore Medical Devices Views

Pages

CT to acquire pacritinib from S*BIO

Cell Therapeutics (CT) has agreed to acquire worldwide rights to S*BIO's pacritinib, a highly selective JAK2 inhibitor. Pacritinib is an oral JAK2 (Janus associated kinase 2) selective inhibitor...

Read article ›

Pages

Filter results

By Geography

By Sector

By Information Type